



**LUNG  
CANCER  
CANADA**

**CANCER  
PULMONAIRE  
CANADA**

AWARENESS. SUPPORT. EDUCATION.

SENSIBILISER. SOUTENIR. ÉDUQUER.

Angie Wong  
Director  
Drug Programs Policy and Strategy Branch (Health)  
Ontario Health - Cancer Care Ontario  
620 University Ave, Toronto, ON M5G 2L7

June 10, 2020

Dear Ms. Wong;

June 7th marked one year since crizotinib for ROS1 positive non-small cell lung cancer (NSCLC) received its Notification to Implement from pCODR. This was a pCODR review that was initiated by Cancer Care Ontario. Today we are writing to you as Lung Cancer Canada (Canada's only national charity solely focussed on lung cancer) and Lung Cancer Canada's Medical Advisory Committee (a group of leading clinicians across Canada) to ask that you to list crizotinib for ROS1 positive NSCLC on the Ontario formulary as soon as possible.

Crizotinib for ROS1 positive NSCLC was approved by Health Canada November 2017. It is an oral treatment that is efficacious and considered a global standard of care. Patients living in Canada have not had access via public coverage, which highlights the significance of CCO's decision to initiate a pCODR review. Now that the PCPA negotiations have concluded Ontario must continue to demonstrate leadership and list this treatment on the public formulary. Quebec has already listed it and Ontario must not fall behind. We understand that testing for ROS1 is inconsistent across the province however those that do test positive should have publicly funded access to the treatment. In fact, a majority of patients do have access to ROS1 testing. By funding the drug that Ontario itself had initiated the call for, it facilitates discussion on viable testing options and we commit to continue working with you to find solutions.

This listing is especially significant as our healthcare system manages the COVID-19 pandemic. As an oral medication, crizotinib for ROS1 NSCLC allows patients to receive treatment outside of the hospital and helps to mitigate potential capacity issues and pressures the pandemic may have placed on the delivery of cancer care Ontario. This listing aligns with OH-CCO efforts to manage capacity and keep patients safe without compromising on their care.

Thank you for your consideration.

Best Regards,

Rosalyn Juergens B.S. (Hons), MD., PhD  
*Chair, Medical Advisory Committee, Lung Cancer Canada*  
Medical Oncology - HHSC Juravinski Cancer Centre  
Chair - Lung Cancer Disease Site Team – Juravinski Cancer Centre  
Head of the Department of Clinical Trials – Juravinski Cancer Centre  
Escarment Cancer Research Institute Scientist  
Associate Professor of Oncology McMaster University  
Adjunct Assistant Professor of Oncology Johns Hopkins University



**LUNG  
CANCER  
CANADA**

**CANCER  
PULMONAIRE  
CANADA**

AWARENESS. SUPPORT. EDUCATION.

SENSIBILISER. SOUTENIR. ÉDUQUER.



Paul Wheatley-Price, BSc, MBChB, FRCP (UK), MD

*President of Lung Cancer Canada*

Associate Professor, Department of Medicine, University of Ottawa

Staff Medical Oncologist and Clinician Investigator, Division of Medical Oncology,

The Ottawa Hospital Cancer Centre, Ottawa

Deputy Division Head – Medical Oncology

Clinical Lead for Lung Cancer – Division of Medical Oncology

Supported by:

Ronald Burkes, MD, FRCPC,

Professor of Medicine, University of Toronto

Medical Oncologist, Mount Sinai Hospital

Parneet Cheema HBSC, MD, MBIOTECH, FRCPC

Medical Oncologist

William Osler Health System

Natasha Leighl, MD MMedSc (Clin Epi) FRCPC FASCO

Professor, Dept. Medicine, University of Toronto,

OSI Pharmaceuticals Foundation Chair in Cancer New Drug Development

Thoracic Site Lead, Division of Medical Oncology

Princess Margaret Cancer Centre/University Health Network

Jeffrey Rothenstein MD, FRCPC

Medical Oncologist - Lakeridge Health

Adjunct Assistant Professor - Queens University